Ligand Pharmaceuticals Incorporated (LGND)

122.11
NASDAQ
Prev Close 122.11
Day Low/High 0.00 / 0.00
52 Wk Low/High 98.56 / 278.62
Exchange NASDAQ
Shares Outstanding 20.45B
Market Cap 2.50B
Div & Yield N.A. (N.A)

Latest News

LGND: Insiders Vs. Shorts

LGND: Insiders Vs. Shorts

The most recent short interest data was recently released for the 02/28/2019 settlement date, and Ligand Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 17.35 "days to cover" versus the median component at 4.57. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ligand To Participate In Four Upcoming Investor Conferences

Ligand To Participate In Four Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Barclays Global Healthcare Conference in Miami.

Ligand Provides Highlights From Today's Analyst Day Event

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business and financial growth outlook.

Notable Wednesday Option Activity: LGND, TLYS, MRNS

Notable Wednesday Option Activity: LGND, TLYS, MRNS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ligand Pharmaceuticals Inc , where a total of 2,471 contracts have traded so far, representing approximately 247,100 underlying shares. That amounts to about 50.7% of LGND's average daily trading volume over the past month of 487,390 shares.

Ligand Sells Promacta Assets And Royalty For $827 Million

Ligand Sells Promacta Assets And Royalty For $827 Million

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand's Promacta ®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for...

Short-Selling Is Really Hard. Just Ask Citron Research

Short-Selling Is Really Hard. Just Ask Citron Research

Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.

Reminder: Ligand To Host Analyst Day On March 12th In New York City

Reminder: Ligand To Host Analyst Day On March 12th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.

Ligand Reports Fourth Quarter And Full Year 2018 Financial Results

Ligand Reports Fourth Quarter And Full Year 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018, and provided an operating forecast and program updates.

Ligand Announces OmniAb® Partnership With Genagon Therapeutics

Ligand Announces OmniAb® Partnership With Genagon Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.

Ligand Announces Investment In Dianomi Therapeutics

Ligand Announces Investment In Dianomi Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces closing an investment in Dianomi Therapeutics, Inc.

Ligand Partner Seelos Therapeutics Becomes A Public Company

Ligand Partner Seelos Therapeutics Becomes A Public Company

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc.

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Nvidia, Microsoft, Kimberly-Clark, Ligand Pharmaceutical, Edison International, Consolidated Edison, ArcBest and more.

Snapping the Win Streak: Cramer's 'Mad Money' Recap (Tuesday 1/22/19)

Snapping the Win Streak: Cramer's 'Mad Money' Recap (Tuesday 1/22/19)

From earnings to oil and fund managers, Jim Cramer breaks down this market action.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Ligand Pharmaceuticals Incorporated

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Ligand Pharmaceuticals Incorporated

The law firm of Kirby McInerney LLP is investigating potential claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND).

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Ligand Pharmaceuticals Incorporated

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Ligand Pharmaceuticals Incorporated

NEW YORK, Jan. 16, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) during the period May 9, 2017 through January 14, 2019, who have...

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Left's firm Citron Research gives the $100+ stock a $35 price target.

Former California Deputy Attorney General And Special Prosecutor With Johnson Fistel Launches Investigation Into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged To Contact Firm

Former California Deputy Attorney General And Special Prosecutor With Johnson Fistel Launches Investigation Into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged To Contact Firm

SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Prosecutor, Tiffany Johnson, Esq.

Ligand To Report Fourth Quarter And Full Year 2018 Results On February 7th

Ligand To Report Fourth Quarter And Full Year 2018 Results On February 7th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2018 financial results on February 7, 2019.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EBR.B Downgrades: AGTC, AL, CAMP, GOLD, LGND, SNV Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Notable Friday Option Activity: LGND, CPE, AAOI

Notable Friday Option Activity: LGND, CPE, AAOI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ligand Pharmaceuticals Inc , where a total volume of 4,974 contracts has been traded thus far today, a contract volume which is representative of approximately 497,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 96.1% of LGND's average daily trading volume over the past month, of 517,610 shares.

Ligand Introduces 2019 Financial Outlook And Raises 2018 Financial Guidance

Ligand Introduces 2019 Financial Outlook And Raises 2018 Financial Guidance

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) introduces its financial outlook for 2019.

Ligand Acquires Milestone And Royalty Rights To PTX-022 From Palvella Therapeutics

Ligand Acquires Milestone And Royalty Rights To PTX-022 From Palvella Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics.

Vernalis Research, A Ligand Company, Achieves Success Milestone In Collaboration With Asahi Kasei Pharma

Vernalis Research, A Ligand Company, Achieves Success Milestone In Collaboration With Asahi Kasei Pharma

Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP).

Ligand Announces OmniAb® Partnership With IMetabolic Biopharma Corporation

Ligand Announces OmniAb® Partnership With IMetabolic Biopharma Corporation

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in Tempe, AZ.

Vernalis Research, A Ligand Company, Achieves Success Milestones In Collaboration With Daiichi Sankyo

Vernalis Research, A Ligand Company, Achieves Success Milestones In Collaboration With Daiichi Sankyo

Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017.

Ligand Reports Third Quarter 2018 Financial Results

Ligand Reports Third Quarter 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates.

Ligand To Participate In Stephens NY Investment Conference

Ligand To Participate In Stephens NY Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in Stephens NY Investment Conference in New York City.

Keysight Technologies Set To Join S&P 500; Ligand Pharmaceuticals To Join S&P MidCap 400; Marcus & Millichap And Arcosa To Join S&P SmallCap 600

Keysight Technologies Set To Join S&P 500; Ligand Pharmaceuticals To Join S&P MidCap 400; Marcus & Millichap And Arcosa To Join S&P SmallCap 600

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Keysight Technologies Inc.

TheStreet Quant Rating: C (Hold)